Mood Stabilizers for Treating Emotional Dysregulation in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD) with or Without Comorbid Bipolar Spectrum Disorders

Overview

Journal Brain Sci

Publisher MDPI

Date 2025 Feb 26

PMID 40002515

Authors

Giulio Emilio Brancati

Ugo De Rosa

Anna Magnesa

Francesco De Dominicis

Alessandra Petrucci

Elisa Schiavi

Pierpaolo Medda

Margherita Barbuti

Giulio Perugi

Affiliations

Soon will be listed here.

Abstract

: The treatment of emotional dysregulation (ED) poses a major challenge for clinicians managing adult attention-deficit/hyperactivity disorder (ADHD). This naturalistic longitudinal study aimed to evaluate the effects of combining mood stabilizers (MS) with standard pharmacotherapy in this population. : Fifty-six adult patients with ADHD, with or without bipolar spectrum disorders, who were followed-up for at least 4 months at Pisa University Hospital were included and grouped based on the prescription of ADHD treatment with prior MS, with conomitant MS and without MS. Changes in self-reported ED, self-reported and informant-reported ADHD severity were assessed using RIPoSt-40, ASRS-v1.1, and CAARS-O:SV. Longitudinal analyses were conducted separately for each group using a pairwise one-sample paired Student's -test. : A significant reduction in ED severity was observed in those treated with methylphenidate (MPH) and concomitant MS and in those with atomoxetine (ATX) without MS. Negative emotionality and emotional impulsivity significantly decreased in both these groups, while affective instability only improved in those with MPH and concomitant MS. Self-reported ADHD improvements were significant in all groups receiving MPH, whether with concomitant, prior, or without MS. Significant changes in informant-reported ADHD severity were found in those receiving MPH with concomitant or prior MS. : The findings highlight the benefits of concomitant MS and MPH treatment on ED, suggest a preferential effect of ATX on negative emotionality, and confirm the effectiveness of MPH for adult ADHD symptoms, regardless of additional treatment with MS. Further studies are needed to explore whether and how MS and MPH may complement each other in reducing ED.

References

Reimherr F, Williams E, Strong R, Mestas R, Soni P, Marchant B . A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry. 2007; 68(1):93-101. DOI: 10.4088/jcp.v68n0113. View

Brancati G, De Dominicis F, Petrucci A, Pallucchini A, Carli M, Medda P . Long-term treatment of adult ADHD in a naturalistic setting: Clinical predictors of attrition, medication choice, improvement, and response. World J Biol Psychiatry. 2023; 24(6):523-538. DOI: 10.1080/15622975.2023.2168750. View

Faraone S, Biederman J, Spencer T, Michelson D, Adler L, Reimherr F . Efficacy of atomoxetine in adult attention-deficit/hyperactivity disorder: a drug-placebo response curve analysis. Behav Brain Funct. 2005; 1:16. PMC: 1262689. DOI: 10.1186/1744-9081-1-16. View

Gjervan B, Hjemdal O, Nordahl H . Functional Impairment Mediates the Relationship Between Adult ADHD Inattentiveness and Occupational Outcome. J Atten Disord. 2013; 20(6):510-8. DOI: 10.1177/1087054712474689. View

Barkley R, Fischer M . The unique contribution of emotional impulsiveness to impairment in major life activities in hyperactive children as adults. J Am Acad Child Adolesc Psychiatry. 2010; 49(5):503-13. DOI: 10.1097/00004583-201005000-00011. View

Reed V, Buitelaar J, Anand E, Day K, Treuer T, Upadhyaya H . The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research. CNS Drugs. 2016; 30(7):603-28. DOI: 10.1007/s40263-016-0349-0. View

Ingenhoven T, Lafay P, Rinne T, Passchier J, Duivenvoorden H . Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials. J Clin Psychiatry. 2009; 71(1):14-25. DOI: 10.4088/jcp.08r04526gre. View

Brancati G, Barbuti M, Pallucchini A, Cotugno B, Schiavi E, Hantouche E . Reactivity, Intensity, Polarity and Stability questionnaire (RIPoSt-40) assessing emotional dysregulation: Development, reliability and validity. J Affect Disord. 2019; 257:187-194. DOI: 10.1016/j.jad.2019.07.028. View

Ravishankar V, Chowdappa S, Benegal V, Muralidharan K . The efficacy of atomoxetine in treating adult attention deficit hyperactivity disorder (ADHD): A meta-analysis of controlled trials. Asian J Psychiatr. 2016; 24:53-58. DOI: 10.1016/j.ajp.2016.08.017. View

10.

Viktorin A, Ryden E, Thase M, Chang Z, Lundholm C, DOnofrio B . The Risk of Treatment-Emergent Mania With Methylphenidate in Bipolar Disorder. Am J Psychiatry. 2016; 174(4):341-348. PMC: 6641557. DOI: 10.1176/appi.ajp.2016.16040467. View

11.

Biederman J, Petty C, Monuteaux M, Evans M, Parcell T, Faraone S . The Child Behavior Checklist-Pediatric Bipolar Disorder profile predicts a subsequent diagnosis of bipolar disorder and associated impairments in ADHD youth growing up: a longitudinal analysis. J Clin Psychiatry. 2009; 70(5):732-40. PMC: 3066229. DOI: 10.4088/JCP.08m04821. View

12.

Mauer S, Ghazarian G, Ghaemi S . Affective Temperaments Misdiagnosed as Adult Attention Deficit Disorder: Prevalence and Treatment Effects. J Nerv Ment Dis. 2023; 211(7):504-509. DOI: 10.1097/NMD.0000000000001626. View

13.

Hirsch O, Chavanon M, Riechmann E, Christiansen H . Emotional dysregulation is a primary symptom in adult Attention-Deficit/Hyperactivity Disorder (ADHD). J Affect Disord. 2018; 232:41-47. DOI: 10.1016/j.jad.2018.02.007. View

14.

Retz W, Stieglitz R, Corbisiero S, Retz-Junginger P, Rosler M . Emotional dysregulation in adult ADHD: What is the empirical evidence?. Expert Rev Neurother. 2012; 12(10):1241-51. DOI: 10.1586/ern.12.109. View

15.

Brancati G, Barbuti M, Schiavi E, Colombini P, Moriconi M, Pallucchini A . Comparison of Emotional Dysregulation Features in Cyclothymia and Adult ADHD. Medicina (Kaunas). 2021; 57(5). PMC: 8151096. DOI: 10.3390/medicina57050489. View

16.

Marchant B, Reimherr F, Robison R, Olsen J, Kondo D . Methylphenidate transdermal system in adult ADHD and impact on emotional and oppositional symptoms. J Atten Disord. 2010; 15(4):295-304. DOI: 10.1177/1087054710365986. View

17.

Sibley M, Eugene Arnold L, Swanson J, Hechtman L, Kennedy T, Owens E . Variable Patterns of Remission From ADHD in the Multimodal Treatment Study of ADHD. Am J Psychiatry. 2021; 179(2):142-151. PMC: 8810708. DOI: 10.1176/appi.ajp.2021.21010032. View

18.

Davids E, Kis B, Specka M, Gastpar M . A pilot clinical trial of oxcarbazepine in adults with attention-deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 30(6):1033-8. DOI: 10.1016/j.pnpbp.2006.03.035. View

19.

Fernandez de la Cruz L, Simonoff E, McGough J, Halperin J, Eugene Arnold L, Stringaris A . Treatment of children with attention-deficit/hyperactivity disorder (ADHD) and irritability: results from the multimodal treatment study of children with ADHD (MTA). J Am Acad Child Adolesc Psychiatry. 2014; 54(1):62-70.e3. PMC: 4284308. DOI: 10.1016/j.jaac.2014.10.006. View

20.

Skirrow C, Asherson P . Emotional lability, comorbidity and impairment in adults with attention-deficit hyperactivity disorder. J Affect Disord. 2012; 147(1-3):80-6. DOI: 10.1016/j.jad.2012.10.011. View